share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/06/24 08:25

Moomoo AI 已提取核心信息

NeuroSense Therapeutics announced significant progress in its Phase 2b PARADIGM clinical trial for ALS treatment, demonstrating a 43% statistically significant slowing of disease progression in high-risk patients treated with PrimeC compared to placebo. The company expects to release 12-month survival data and additional biomarker results in June 2024, with an FDA meeting anticipated in Q3 2024.Q1 2024 financial results showed R&D expenses of $1.88 million and G&A expenses of $1.11 million, remaining steady compared to Q1 2023. As of March 31, 2024, the company had $0.74 million in cash, supplemented by a subsequent $4.5 million financing completed in April 2024 through a registered direct offering of ordinary shares and warrants.The company is preparing for Phase 3 clinical trials with protocol submission expected by year-end 2024. NeuroSense has also changed its accounting method from IFRS to U.S. GAAP and reissued its 2023 financial statements accordingly. Management continues to pursue partnership discussions to advance their clinical programs efficiently.
NeuroSense Therapeutics announced significant progress in its Phase 2b PARADIGM clinical trial for ALS treatment, demonstrating a 43% statistically significant slowing of disease progression in high-risk patients treated with PrimeC compared to placebo. The company expects to release 12-month survival data and additional biomarker results in June 2024, with an FDA meeting anticipated in Q3 2024.Q1 2024 financial results showed R&D expenses of $1.88 million and G&A expenses of $1.11 million, remaining steady compared to Q1 2023. As of March 31, 2024, the company had $0.74 million in cash, supplemented by a subsequent $4.5 million financing completed in April 2024 through a registered direct offering of ordinary shares and warrants.The company is preparing for Phase 3 clinical trials with protocol submission expected by year-end 2024. NeuroSense has also changed its accounting method from IFRS to U.S. GAAP and reissued its 2023 financial statements accordingly. Management continues to pursue partnership discussions to advance their clinical programs efficiently.
NeuroSense Therapeutics有限公司是一家专注于神经退行性疾病的生物技术公司，于2024年6月24日宣布了其2024年第一季度财务报告并提供了公司的最新动态。公司报告了188万美元的研发费用，与去年的185万美元相符，将其稳定性归因于增加的分包商和顾问费用抵消了减少的股票报酬费用。总部行政费用从2023年的114万美元略有降低至2024年的111万美元。NeuroSense在本季度结束时的现金为740,000美元，不包括最近一轮450万美元的融资。公司还将会计方法从IFRS转换为美国通用会计准则，因此重新发布了其2023年的财务报表。NeuroSense的首席执行官Alon ...展开全部
NeuroSense Therapeutics有限公司是一家专注于神经退行性疾病的生物技术公司，于2024年6月24日宣布了其2024年第一季度财务报告并提供了公司的最新动态。公司报告了188万美元的研发费用，与去年的185万美元相符，将其稳定性归因于增加的分包商和顾问费用抵消了减少的股票报酬费用。总部行政费用从2023年的114万美元略有降低至2024年的111万美元。NeuroSense在本季度结束时的现金为740,000美元，不包括最近一轮450万美元的融资。公司还将会计方法从IFRS转换为美国通用会计准则，因此重新发布了其2023年的财务报表。NeuroSense的首席执行官Alon Ben-Noon强调了其领先药物候选PrimeC在2b PARADIGM临床试验中取得的积极成果，该药物显示出显著减缓ALS病程。公司预计将在2024年6月分享12个月的临床结果和额外的生物标志物数据，FDA会议预计在2024年第三季度举行，并为在美国进行第三期临床试验做好准备。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！